Evaluating Ceftriaxone 80 mg/kg Administration by Rapid Intravenous Infusion-A Clinical Service Evaluation.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 02 2021
01 02 2021
Historique:
pubmed:
10
11
2020
medline:
24
8
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
In pediatric ambulatory care, the speed of medication infusion can have major impact on healthcare staff workload and the number of children able to be treated by services designed to reduce inpatient length of stay. In many regions of the world, local and supraregional guidelines allow ceftriaxone infusions of ≥50 mg/kg in infants and children up to 12 years of age to be given over 10 minutes. The generic European summary of product characteristics for ceftriaxone does not state a specific infusion time for this dose range, although 1 manufacturers' summary of product characteristics in the United Kingdom states a 30-minute minimum infusion time. We conducted a formal service evaluation of a change in practice at a large UK pediatric children's hospital and demonstrated the clinical feasibility, safety, and high parent satisfaction of 10-minute ceftriaxone infusions for prescribed doses ≥50 mg/kg. This approach can improve patient flow within hospital-based ambulatory services as well as by community nursing teams administering antibiotics at home.
Identifiants
pubmed: 33165272
pii: 00006454-202102000-00010
doi: 10.1097/INF.0000000000002923
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ceftriaxone
75J73V1629
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-129Subventions
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Patel S, Burzio V, Green H, et al. The impact of pediatric outpatient parenteral antibiotic therapy implementation at a tertiary children’s hospital in the United Kingdom. Pediatr Infect Dis J. 2018; 37:e292–e297.
Hodgson KA, Huynh J, Ibrahim LF, et al. The use, appropriateness and outcomes of outpatient parenteral antimicrobial therapy. Arch Dis Child. 2016; 101:886–893.
Ceftriaxone 1g Powder for solution for injection. Available from: https://www.medicines.org.uk/emc/product/1361/smpc#POSOLOGY . Accessed September 9, 2019.
Rocephin 1g Powder for Solution for Injection or Infusion. Available from: https://www.medicines.org.uk/emc/product/7933/smpc#POSOLOGY (section 4.2). Accessed September 9, 2019.
UMass Memorial Medical Center. Pediatric Guidelines for IV Medication Administration. Available from: https://www.umassmed.edu/globalassets/anesthesiology/files/resources/2016-resources/pediatric-guidelines-for-medications.pdf . Accessed September 9, 2019.
Ceftriaxone Neonatal. Available from: https://www.kemh.health.wa.gov.au/~/media/Files/Hospitals/WNHS/For%20health%20professionals/Clinical%20guidelines/NCCU/Drug%20Protocols/Ceftriaxone.pdf . Accessed September 9, 2019.
Goldwater PN. Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. Int J Antimicrob Agents. 2005; 26:408–411.
European Medicines Agency. 1.3.1.1 Summary of Product Characteristics. Available from: http://mri.cts-mrp.eu/download/NL_H_1622_003_FinalSPC.pdf . Accessed October 15, 2020.